{
  "abstract": "We thank Dr Yang and colleagues for their interest in the HELIOS trial and their thoughtful appraisal of our findings.1 2",
  "authors": [
    {
      "affiliations": [
        "Inflammatory Bowel Disease Centre, Department of Gastroenterology and Hepatology, Radboudumc, Nijmegen, The Netherlands"
      ],
      "name": "Maarten te Groen"
    },
    {
      "affiliations": [
        "Inflammatory Bowel Disease Centre, Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands"
      ],
      "name": "Anouk M Wijnands"
    },
    {
      "affiliations": [
        "Inflammatory Bowel Disease Centre, Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands"
      ],
      "name": "Bas Oldenburg"
    },
    {
      "affiliations": [
        "Inflammatory Bowel Disease Centre, Department of Gastroenterology and Hepatology, Radboudumc, Nijmegen, The Netherlands",
        "Department of Gastroenterology, Division of Medicine, University of Alberta, Edmonton, Alberta, Canada"
      ],
      "name": "Frank Hoentjen"
    }
  ],
  "title": "Reply to ‘Critical appraisal of the HELIOS study on surveillance in IBD patients’",
  "uid": "f01497a9-5be5-573d-8c2d-9667d9219315"
}